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Abstract
Background: Cancer/testis antigens (CTAs) were first discovered as immunogenic targets normally expressed in germline
cells, but differentially expressed in a variety of human cancers. In this study, we used an integrative epigenetic screening
approach to identify coordinately expressed genes in human non-small cell lung cancer (NSCLC) whose transcription is
driven by promoter demethylation.
Methodology/Principal Findings: Our screening approach found 290 significant genes from the over 47,000 transcripts
incorporated in the Affymetrix Human Genome U133 Plus 2.0 expression array. Of the top 55 candidates, 10 showed both
differential overexpression and promoter region hypomethylation in NSCLC. Surprisingly, 6 of the 10 genes discovered by
this approach were CTAs. Using a separate cohort of primary tumor and normal tissue, we validated NSCLC promoter
hypomethylation and increased expression by quantitative RT-PCR for all 10 genes. We noted significant, coordinated
coexpression of multiple target genes, as well as coordinated promoter demethylation, in a large set of individual tumors
that was associated with the SCC subtype of NSCLC. In addition, we identified 2 novel target genes that exhibited growth-
promoting effects in multiple cell lines.
Conclusions/Significance: Coordinated promoter demethylation in NSCLC is associated with aberrant expression of CTAs
and potential, novel candidate protooncogenes that can be identified using integrative discovery techniques. These
findings have significant implications for discovery of novel CTAs and CT antigen directed immunotherapy.
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Introduction
It is well known that CTAs are overexpressed in various tumor
types, with little or no expression in normal human tissue; however,
the mechanism of this differential expression is not well understood
[1]. Epigenetic changes including alterations in promoter methyl-
ation have been associated with cancer-specific expression differ-
ences in human malignancies, including non-small cell lung
carcinoma (NSCLC) [2,3,4,5,6,7]. Promoter hypermethylation
has primarily been considered as a mechanism of tumor suppressor
gene inactivation; however, global genomic hypomethylation has
been reported in almost all tumors [2,4,8,9]. It is also known that
CTAs, especially those encoded by the X chromosome (CT-X
antigens), are expressed in association with promoter demethylation
or whole genomic hypomethylation [10,11,12].
Lung cancer is the leading cause of cancer-related deaths worldwide,
with over 213,000 new cases and 160,000 deaths reported in 2007;
NSCLC accounts for approximately 75% of these cases [13]. The high
mortality rate in NSCLC is attributable to diagnosis at an advanced
stage, a high rate of recurrence despite definitive locoregional
management, and the fact that no therapies for recurrent lung cancer
have been associated with improved long-term survival [6].
One approach to improve NSCLC mortality has been the
development of cancer vaccines which aim to induce a host
immune response against tumor cells. CTAs are attractive targets
for tumor immunotherapy because of their restricted expression
patterns in normal human tissue. For example, NY-ESO-1 and
MAGEA3 are currently undergoing clinical trials in various
human malignancies, including NSCLC. Investigators have
suggested that combined use of coordinately expressed CTAs
and other associated antigens could aid in the design of more
effective, polyvalent immunotherapeutic protocols in NSCLC and
other tumor types; however, there is currently very little known
about the coexpression patterns of these genes [14,15,16].
To date, a comprehensive, genome-wide approach to identify
coordinately expressed CTAs and other differentially expressed
genes activated by promoter demethylation in NSCLC has not
been conducted. In this study, we used a novel, integrative
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epigenetic screening approach combining 5-aza-deoxycytidine and
trichostatin A (5-aza/TSA) treatment of normal lung cells and
mRNA microarray expression analysis of primary tissue to identify
genes that are both activated by DNA hypomethylation and
differentially upregulated in a coordinated fashion in NSCLC. We
were able to define a set of coordinately expressed CTAs and
novel, growth promoting genes that are activated in association
with coordinated promoter demethylation. These data have
implications for the mechanism of activation of CTAs, design of
immunotherapeutic strategies, as well as identification of potential
protooncogenes and novel biologic targets for gene directed
therapies for NSCLC.
Materials and Methods
Histopathology
All samples were analyzed by the pathology department at Johns
Hopkins Hospital. Tissues were obtained via Johns Hopkins
Institutional Review Board approved protocol NA_00001911.
Written informed consent was obtained from each subject prior to
the use of their tissue for scientific research. Tumor and normal lung
tissues from surgical specimens were frozen in liquid nitrogen
immediately after surgical resection and stored at 280uC until use.
Normal samples were microdissected and DNA prepared from
normal lung parenchyma. Tumor samples were confirmed to be
NSCLC and subsequently microdissected to yield at least 80% tumor
cells. Tissue DNA and RNA was extracted as described below.
5Aza-dC and TSA Treatment of Cells
We treated normal human lung cell lines (NHBE and SAEC,
Lonza, Walkersville, MD) in triplicate with 5-aza-deoxycytidine (a
cytosine analog which cannot be methylated) and trichostatin A (a
histone deacetylase inhibitor) as described previously [17]. Briefly,
cells were split to low density (2.56105 cells and 66105/100 mm
dish for SAEC and NHBE respectively) 24 hours before
treatment. Stock solutions of 5Aza-dC (Sigma, St. Louis, MO)
and TSA (Sigma) were dissolved in 50% acetic acid and 100%
ethanol, respectively. Cells were treated with 5 uM 5Aza-
deoxycytidine for 72 hours and 300 nmol/L TSA for the last
24 hours. Baseline expression was established by mock-treated
cells with the same volume of acetic acid or ethanol in triplicate.
RNA Extraction and Oligonucleotide Microarray Analysis
Total cellular RNA was isolated using Trizol (Life Technologies,
Gaithersburg, MD) and the RNeasy kit (Qiagen, Valencia, CA)
according to the manufacturer’s instructions. We carried out
oligonucleotide microarray analysis using the GeneChip U133
Plus 2.0 Affymetrix expression microarray (Affymetrix, Santa
Clara, CA). Samples were converted to labeled, fragmented,
cRNA per the Affymetrix protocol for use on the expression
microarray. Signal intensity and statistical significance was
established for each transcript using dChip version 2005 to
initially analyze and normalize the array data and then
Significance Analysis of Microarrays (SAM) [18]. SAM output
was calculated at a d-value of 1.126 yielding a false discovery rate
and d-score cutoff of 5.065% and 1.885. This identified a total of
12,132 upregulated candidate genes after 5Aza-dC/TSA treat-
ment. All microarray data is MIAME compliant, and the raw data
has been deposited in a MIAME compliant database, GEO, as
detailed by the MGED Society.
Public Datasets
The public databases used in this study were the University of
California Santa Cruz (UCSC) Human Genome reference
sequence and the annotation database from the March 2006
freeze (hg18). We obtained 40 normal lung and 111 NSCLC
expression microarrays from the expO datasets (all performed on
the Affymetrix U133 Plus 2.0 mRNA expression platform)
available online as part of the Gene Expression Omnibus
(GEO/NCBI). Accession numbers for these arrays are GSE1643
and GSE3141 respectively. The microarrays from normal tissue
and tumor were first normalized for COPA analysis using dChip
version 2005.
Cancer Outlier Profile Analysis (COPA)
We applied COPA to our cohort of 151 tissues (111 tumors, 40
normals), with each gene expression data set containing 54,613
probe sets from the Affymetrix U133 Plus 2.0 mRNA expression
platform. Briefly, gene expression values were median centered,
setting each gene’s median expression value to zero. The median
absolute deviation (MAD) was calculated and scaled to 1 by
dividing each gene expression value by its MAD. Of note, median
and MAD were used for transformation as opposed to mean and
standard deviation so that outlier expression values do not unduly
influence the distribution estimates, and are thus preserved post-
normalization. Finally, the 75th, 90th, and 95th percentiles of the
transformed expression values are calculated for each gene and
then genes were rank-ordered by their percentile scores, providing
a prioritized list of outlier profiles. For the purposes of our rank-
list, the 90th percentile for tumors was chosen based on sample-
size analysis (111 tumors, 40 normals). Normal tissue that had a
95th percentile .2 was eliminated from our rank list. A total of
35,764 transcripts met the above criteria and were ranked. For
details of the method refer to Tomlins et. al [19].
Integrative Epigenetics
We ranked target genes from the Affymetrix U133 Plus 2.0
mRNA expression platform by COPA upregulation at the 90th
percentile (from 111 tumors and 40 normal tissues). The U133 Plus
2.0 mRNA expression platform (Affymetrix, Santa Clara California)
has approximately 55,000 probe sets. A second rank list was
produced by ranking genes in descending order of their d-score as
computed by SAM following 5-aza/TSA treatment of normal lung
cell lines (NHBE and SAEC). A third rank list was computed using
111 NSCLC and an additional expO dataset with 79 additional
NSCLC primary tumor tissues also run on the Affymetrix Human
Genome U133 Plus 2.0 mRNA expression platform. In these 190
primary NSCLC samples, we correlated BORIS expression
patterns within each tumor with expression of all transcripts
incorporated in the U133 Plus 2.0 array by calculating a correlation
coefficient using Excel. All genes were then ranked based on the
strength of the correlation between their expression and that of
BORIS expression across all 190 samples. These three sources of
information (gene set demonstrating upregulation with 5-aza,
COPA score, and BORIS correlation) were combined by using a
rank product (x*y*z). These three rankings were combined to rank
all targets and permutation of the data was used to establish
significance with a threshold of a=0.005, yielding 290 significant
genes. Genomic sequences were obtained for 122 of these genes
using the UCSC genome browser, and the presence of CpG islands
in the promoters or first intron of these genes was determined by
MethPrimer which relies on GC content of.50%,.100 bp,.0.6
observed to expected CG’s [20].
DNA Extraction
Samples were centrifuged and digested in a solution of detergent
(sodium dodecylsulfate) and proteinase K, for removal of proteins
bound to the DNA. DNA was purified by phenol-chloroform
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extraction and ethanol precipitation. The DNA was subsequently
resuspended in 500 mL of LoTE (EDTA 2.5 mmol/L and Tris-
HCl 10 mmol/L) and stored at 280uC until use.
Bisulfite Treatment and Sequencing
2 ug of DNA from 28 NSCLCs and 11 normal lung tissues were
subjected to bisulfite treatment using the EpiTectH Bisulfite Kit
(Qiagen, Valencia, CA) according to the manufacturer’s instruc-
tions. This bisulfite-modified DNA was then stored at 280uC.
Subsequently, bisulfite-treated DNA was amplified using primers
designed by MethPrimer to span areas of CpG islands in the
promoter or first intron [20]. Primer sequences were designed to
not contain CG dinucleotides. Primer sequences are available in
Table S1. Touch down PCR was performed and products were
gel-purified using the QIAquick Gel Extraction Kit (Qiagen,
Valencia, CA), according to the manufacturer’s instructions. Each
amplified DNA sample was applied with nested primers to the
Applied Biosystems 3700 DNA analyzer using BD terminator dye
(Applied Biosystems, Foster City, CA).
Quantitative RT-PCR
Total RNA extracted as described above and the concentration
for each sample was measured. 1 ug of RNA was then used for
cDNA synthesis performed using oligo-dt with the SuperScript
First- Strand Synthesis kit (Invitrogen, Carlsbad, CA). The final
cDNA products were used as the templates for subsequent RT-
PCR with primers designed specifically for each candidate gene.
18s rRNA was examined to ensure accurate relative quantitation
in quantitative RT-PCR. Each experiment was performed in
triplicate using the TAqMan 7900 (ABI) real-time PCR machine
and the QuantiFast SYBR Green PCR Kit (Qiagen, Valencia,
CA) according to the manufacturer’s instructions. Primer
sequences are available in Table S1.
Quantitative Unmethylation-Specific PCR (QUMSP)
To selectively amplify demethylated promoter regions in genes
of interest, primers were designed using data from bisulfite
sequencing of primary tumors which are complimentary only to
bisulfite-converted sequences known to be demethylated in
tumors. Primer combinations were validated using in vitro
methylated and demethylated controls. These experiments were
performed in triplicate using the TAqMan 7900 (ABI) real-time
PCR machine with standard curves and normalization to Beta-
Actin primers that do not contain CpG’s in the sequence for
quantitation. Primer sequences are available in Table S1.
Transfection of Human Expression Vectors and AD
Growth Assay
A full-length ORF cDNA of SBSN and NY-ESO-1 were obtained
for transient transfections from Origene in a pCMV6-Entry vector
(Rockville, Maryland). Cell lines were plated at 56105 cells/well
using 6-well plates and transfected with either empty vector or vector
containing the gene of interest using the FuGene 6 Transfection
Reagent (Roche, Basel, Switzerland) according to the manufacturer’s
protocol. Cell Counting Kit-8 (CCK-8) (Dojindo; Rockville,
Maryland) absorbance was measured by the Spectramax M2e 96-
well fluorescence plate reader Molecular Devices (Sunnyvale,
California). All AD growth experiments were performed in triplicate
for all cell lines and vectors.
Anchorage-Independent Growth Assay
Soft agar assays were conducted following transfection of cells
with mammalian pCMV6-Entry expression vectors containing a
G418 resistance cassette (Origene). Cells were counted and
approximately 5000 were added into each 6 well plate. The
bottom layer was composed of 0.5% agar, RPMI +10% FBS,
while the cells were suspended in a top layer of 0.35% agar, RPMI
+10% FBS and G418 (300 ug/ml). Soft agar assays were
incubated at 37 degrees for 12 days. All experiments were
performed in triplicate for all cell lines and vectors.
Statistical Analysis
We looked for similarities in the methylation patterns between
genes by performing an analysis of correlations between QUMSP
readings on the genes across all samples. Spearman’s correlation
permutation testing was used with 1000 permutations of the
samples to establish significance, with a=0.05. For the expression
data, we log-transformed the normalized data and performed
correlation analysis across all samples between each of the genes in
the study. Significance was determined by assuming a normal
distribution in the log-transformed expression levels and applying
Student’s t-distribution with an alpha of 0.05. All analyses were
performed using Matlab.
Results
A Novel Integrative Epigenetic Approach to Screen for
CTAs and Related Epigenetically Regulated Genes
We developed an integrative, high-throughput approach to
screen for CTAs and other coordinately expressed genes based on
three key previously published factors: (1) CTAs are expressed in
germline cells and many tumors, but not in normal somatic tissue
[1,21], (2) CTAs have promoter CpG islands that are methylated
and silenced in normal somatic tissue, but, experimentally, can be
expressed by promoter demethylation [1,10,11,12] and (3) the
transcription factor BORIS has been shown to induce de-
repression of several CTAs in NSCLC and other tumor/tissue
types (Figure 1A) [22,23,24,25].
The first arm of our screening approach involved the
pharmacologic demethylation of 2 normal lung cell lines, Normal
Human Bronchial Epithelial (NHBE) and Human Small Airway
Epithelial (SAEC) cells (Lonza, Walkersville, MD), using a 5-aza/
TSA treatment protocol that has previously been successful in
defining candidate tumor suppressor genes by demethylating
tumor cell lines. With the understanding that CTAs are silenced
by methylation in normal tissue, we used normal cell lines to
identify genes that are typically repressed in normal tissues, but
can be re-expressed by pharmacologic manipulation. Two normal
lung cell lines, NHBE and SAEC, were treated with 5 mM 5-aza
deoxycytidine for 72 hours and Trichostatin A for 24 hours prior
to harvesting total RNA for expression array analysis using the
Affymetrix Human Genome U133 Plus 2.0 expression platform.
These results were then analyzed using dChip and Significance
Analysis of Microarrays (SAM) [17,18]. Genes were ranked based
on their SAM score(d). SAM also reported the fold change in the
mean expression of the target genes in the 5-aza/TSA treatment
group versus the control group (Figure 1B).
We concurrently analyzed data from 40 normal lung and 111
NSCLC expression microarrays from expO datasets (all run on the
Affymetrix Human Genome U133 Plus 2.0 mRNA expression
platform) publically available online as part of the Gene
Expression Omnibus (GEO/NCBI). For our analysis of these
151 primary tissue expression array data sets, we used a technique
known as Cancer Outlier Profile Analysis (COPA). COPA is a
method to search for marked overexpression of particular genes
that occur only in a subset of cases, whereas traditional analytical
methods based on standard statistical measures fail to find genes
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with this type of expression profile [19]. COPA was a particularly
useful method for us to search for CTAs and genes with similar
expression profiles based on previous studies showing that CTAs
are heterogeneously expressed both across a wide patient
population and within individual tumor specimens [26,27,28].
Genes with a normal tissue COPA expression scaled score .2 at
the 95th percentile were eliminated from the rank list. All
remaining genes were then ranked based on their COPA score at
the 90th percentile; statistical significance of the expression
differences in the COPA diagrams were measured by Mann-
Whitney U test (Figure 1C).
For the final arm of our screening approach, we used the previous
data set with 111 NSCLC and an additional expO dataset with 79
additional NSCLC primary tumor tissues also run on the Affymetrix
Human Genome U133 Plus 2.0 mRNA expression platform. In
these 190 primary NSCLC samples, we correlated BORIS
expression patterns within each tumor with expression of all
transcripts incorporated in the U133 Plus 2.0 array by calculating a
correlation coefficient using Excel. All genes were then ranked
based on the strength of the correlation between their expression
and that of BORIS expression across all 190 samples.
Three rank lists were produced by ranking genes by SAM
score(d) following 5-aza/TSA treatment in normal lung cell lines,
COPA score in primary tissue, and BORIS correlation in primary
tissue. These 3 rank lists were combined by using a rank product
(x*y*z). Using a significance threshold (a=0.005) and subsequent
random permutations of our rank-lists, we identified 290 genes
that were significantly differentially upregulated based on
epigenetic screening and tissue microarray expression patterns
(Table S2) [29].
Initially, an in silico approach utilizing MethPrimer was used to
confirm the presence of CpG islands in the promoter regions of
our top candidates [20]. The top 100 of the 290 significant genes
as well as 22 genes selected based on biological relevance in cancer
related pathways were selected to be screened via this approach,
and 101 were found to contain 1 or more promoter CpG islands.
We then used a separate cohort of 11 normal lung tissues from
patients without a cancer diagnosis to confirm epigenetic silencing
via promoter methylation in normal lung mucosa from patients
without a lung neoplasm. Bisulfite sequencing of CpG islands in
the promoter regions of 55 selected gene targets with CpG islands
was used to determine the methylation status. Only 17/55
Figure 1. Integrative epigenetic screening strategy. (A) Schematic outline of the integrative epigenetic screening strategy utilized in this study
which combined the pharmacologic demethylation of normal cell lines, comparative COPA anaylsis in primary tissue and correlation of gene
expression with the epigenetic regulator BORIS in primary tissue. (B) Representative COPA graph of MAGEA12 demonstrating the statistical approach
used to find candidate overexpressed CTAs and related genes. Difference in tumor versus normal expression was significant, p value,0.00001 as
measured by Mann-Whitney U test. (C) Upfold regulation of mRNA expression in treated normal lung cell lines, NHBE and SAEC, as measured by
Affymetrix Human Genome U133 Plus 2.0 mRNA expression platform.
doi:10.1371/journal.pone.0008189.g001
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promoter regions demonstrated complete methylation at all
sequenced CpG sites in all or nearly all of the normal tissues
(Table S2). These targets were subsequently bisulfite sequenced in
a separate cohort of 28 primary NSCLC to search for the presence
of promoter hypomethylation. Of these remaining targets, 10/17
showed promoter demethylation in some fraction of tumors
including: MAGEA3 (13/28, p= 0.0067), MAGEA12 (19/28,
p = 0.0001), MAGEA4 (9/27, p = 0.0378), MAGEA1 (21/27,
p = 0.0001), SBSN (13/28, p = 0.0067), TKTL1 (5/27,
p = 0.2949), MAGEA5 (9/23, p= 0.0172), ZNF711 (21/24,
p = 0.0001), NY-ESO-1 (14/20, p = 0.0002), G6PD (17/18,
p = 0.0014), (Fisher’s exact test, two-sided) (Table 1 and Figure 2).
Transcriptional upregulation of target genes after 5-aza/TSA
treatment in our cell line system was confirmed using quantitative
RT-PCR on the 5-aza/TSA-treated normal cells compared to
mock-treated cells for these 10 genes (Figure S1). Each gene with
the exception MAGEA12 demonstrated significant upregulation by
5-aza/TSA treatment in at least one cell line supporting functional
gene regulation by promoter hypomethylation.
CTAs and Associated Genes Are Coordinately
Demethylated and Expression Is Correlated with
Promoter Demethylation
In order to confirm the bisulfite sequencing results in our target
genes and to provide a dataset of continuous variables to express the
status of promoter demethylation, we devised a rapid, quantitative
assay for specifically measuring non-methylated promoters, which
we termed Quantitative Unmethylation-Specific PCR (QUMSP).
We assayed DNA extracted from our cohort of 28 primary NSCLC
tumor samples and 11 normal lung samples from non-cancer
patients (Figure 3A). Significant tumor-specific demethylation was
found in MAGEA3 (p,0.005), MAGEA12 (p,0.025), MAGEA4
(p,0.018), MAGEA1 (p,0.001), TKTL1 (p,0.025) and MAGEA5
(p,0.007). Two additional targets slightly missed significance at
a,0.05, SBSN (p,0.07) and NY-ESO-1 (p,0.09) (2 tailed Student’s
t-test assuming unequal variance).
Given the tumor-specific demethylation pattern seen for our
target genes, we next wanted to determine if demethylation of the
promoter regions of these genes occurred in a coordinated fashion
within tumor samples. We utilized the Spearman’s correlation
permutation testing to determine significant coordinated demeth-
ylation using the QUMSP results from our cohort of 28 NSCLC
(Figure 3B). The p-value matrix of the Spearman’s correlation
coefficient shows that for any of the target genes, demethylation
tended to coordinately occur with a minimum of 6 of the other
genes. Shaded cells represent significant p-values. This offers
evidence that demethylation is highly associated with coordinated
regulation of these CTAs and related target genes in NSCLC, and
strongly suggests an epigenetic mechanism of activation.
In order to confirm tumor specific expression of our target
genes, we used quantitative RT-PCR to determine mRNA
expression in our cohort of NSCLC and normal lung tissue
(Figure S2A2J). Six genes had significantly increased expression in
tumors MAGEA12 (p,0.02), SBSN (p,0.002), TKTL1 (p,0.02),
ZNF711 (p,0.008), NY-ESO-1 (p,0.001), G6PD (p,0.006). Three
genes slightly missed significance at the a,0.05 level: MAGEA3
(p,0.09), MAGEA4 (p,0.06) and MAGEA1 (p,0.08) (2 tailed
Student’s t-test assuming unequal variance).
We next wanted to determine if demethylation was responsible
for the derepression of the CTAs and related genes in NSCLC.
Four target genes showed a significant positive correlation between
mRNA expression (quantitative RT-PCR) and promoter hypo-
methylation (QUMSP): MAGEA12 (p = 0.024), MAGEA4
(p,0.004), SBSN (p = 0.004) and NY-ESO-1 (p,0.004) (Figure
S3A2D) (Spearman’s correlation permutation test). TKTL1
(p = 0.1), MAGEA5 (p = 0.104) and MAGEA3 (p = 0.2) also showed
a positive correlation between demethylation and expression, but
missed significance (Table S3). These data suggest demethylation
of promoter regions is partially responsible for the regulation of the
majority of our target genes.
CTAs and Associated Target Genes Are Coordinately
Expressed
Given the findings in the previous analyses of our cohort of
primary tissue showing that these target genes are differentially
expressed in tumors, their promoter regions are coordinately
demethylated within tumors and expression is correlated with
demethylation, we examined our initial cohort of 111 tumors
assayed using the Affymetrix Human Genome U133 Plus 2.0
mRNA expression platform to determine if our target genes were
Table 1. List of 10 genes elucidated by our integrative epigenetic screening approach and found to be coordinately expressed
and demethylated in NSCLC.
Symbol Description
Integrated
Rank Position
COPA
Score*
Upregulatedwith 5-Aza
Average Fold Change
(SAMScore (d))
Promoter CpG
Island Present
Methylated in
Normal Lung Tissue
Unmethylated
in NSCLC
Tumor Tissue
MAGEA3 Melanoma antigen family A, 3 4 60.6 1.8 (9.9) Y Y Y
MAGEA12 Melanoma antigen family A, 12 5 24.1 4.8 (7.8) Y Y Y
MAGEA4 Melanoma antigen family A, 4 6 101.0 14.9 (11.3) Y Y Y
MAGEA1 Melanoma antigen family A, 1 11 12.8 6.5 (10.5) Y Y Y
SBSN Suprabasin 27 6.4 13.5 (31.3) Y Y Y
TKTL1 Transketolase-like 1 35 1.8 3.5 (15.3) Y Y Y
MAGEA5 Melanoma antigen family A, 5 41 16.9 1.5 (3) Y Y Y
ZNF711 Zinc finger protein 6 43 10.0 3.8 (9.3) Y Y Y
NY-ESO-1 Cancer/testis antigen 1B 72 117.6 5.9 (4) Y Y Y
G6PD Glucose-6-phosphate
dehydrogenase
105 22.4 2.1 (10.6) Y Y Y
*Tumor COPA score at 90th percentile.
doi:10.1371/journal.pone.0008189.t001
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coordinately expressed within tumor samples in this large sample
set. Figure 4A shows a heat map of transcript expression as
measured by the U133 Plus 2.0 array for 40 normal lung samples
from non-cancer patients and 111 NSCLC primary tissue samples.
This figure visualizes the relationship of expression between the 10
target genes in normal and tumor samples. The data were first
normalized by setting the mean and standard deviation of each
gene to 0 and 1 respectively across all 151 samples. The data were
Figure 2. Promoter methylation status in primary tissues. Shown are the bisulfite sequencing results with associated p values in 28 NSCLC
tumor samples and 11 normal lung tissues for: MAGEA3 (13/28, p = 0.0067), MAGEA12 (19/28, p = 0.0001), MAGEA4 (9/27, p = 0.0378), MAGEA1 (21/27,
p = 0.0001), SBSN (13/28, p = 0.0067), TKTL1 (5/27, p = 0.2949), MAGEA5 (9/23, p = 0.0172), ZNF711 (21/24, p = 0.0001), NY-ESO-1 (14/20, p = 0.0002),
G6PD (17/18, p = 0.0014). In parentheses are the ratio of demethylated promoters in tumors and the p-values as calculated by the Fisher’s exact test
comparing demethylation in tumors vs. normals. Shaded boxes represent methylated promoters, ND=methylation status not determined by bisulfite
sequencing.
doi:10.1371/journal.pone.0008189.g002
Figure 3. CTAs and associated genes are coordinately demethylated. (A) QUMSP was conducted in our cohort of 28 NSCLC and 11 normal
lung tissues. Experiments were performed in triplicate, mean values are shown representing the percentage of unmethylated promoters on a
logarithmic scale. Statistically significant tumor-specific demethylation was found in MAGEA3, MAGEA12 (p,0.025), MAGEA4 (p,0.018), MAGEA1
(p,0.001), TKTL1 (p,0.025) and MAGEA5 (p,0.007). Two additional targets slightly missed significance at a,0.05, SBSN (p,0.07) and NY-ESO-1
(p,0.09) (2 tailed Student’s t-test assuming unequal variances). (B) Promoter hypomethylation (QUMSP) correlation p-value matrix for NSCLC (n = 28;
Spearman’s correlation permutation test). Shaded cells represent significant p-values.
doi:10.1371/journal.pone.0008189.g003
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then clustered in the sample domain using hierarchical clustering
with average linkage and a Euclidean distance metric. This
provided three clusters: 1) all 40 normal samples, 2) 43 of the 111
tumor samples showing high expression in most of the genes and
strong correlations between them (Tumor 1), and 3) 52 of 111
tumor samples showing lower expression but with expression still
above normals (Tumor 2). The remaining 16 of 111 tumor
samples did not cluster together or in these groups. This analysis
not only provided confirmation that expression of our target genes
is limited to a subset of tumors with little or no expression in the
normal tissue, but also, that these targets appear to be coordinately
expressed in a large subset, 38.7%, of these tumors.
In addition, the data show that there is a distinct correlation
between the coordinated expression of these 10 target genes and the
squamous cell carcinoma (SCC) subtype of NSCLC. In the group
Tumor 1 72% of the samples were of the SCC subtype, whereas
only 23% of tumors in Tumor group 2 were SCCs, p,0.00001
(Fisher’s exact test, two-sided), OR=8.4, 95% CI 3.1224.3.
To formally test the coordinate expression of these genes, we next
constructed a p-value matrix derived from the Pearson’s correlation
coefficients calculated between the expression levels of each target
(Figure 4B). Values to the upper right have been corrected with the
Benjamin Hochberg multiple test correction to decrease the false
discovery rate; however, there is no change in significance after this
correction (uncorrected values displayed in lower left). Shaded cells
represent significant p-values. Using this pairwise comparison
method, we found highly significant coordinated upregulation of
all 10 target genes within a subset of tumor samples.
SBSN and NY-ESO-1 Are Growth Promoting in Normal and
NSCLC Cell Lines
We performed transient transfections in multiple NSCLC and
normal cell lines in order to gain insight into the function of NY-
ESO-1 and newly identified SBSN, two genes that showed
significant correlation between promoter hypomethylation and
transcriptional upregulation in primary tumor tissue. In lung
squamous cell carcinoma cell lines NCI-H1703 and NCI-H226,
transient transfection of a construct containing either NY-ESO-1 or
SBSN caused a significant increase in anchorage dependent (AD)
cell growth. In H1703 cells at 72 hours, NY-ESO-1 and SBSN
caused a 23% (612%) and 47% (66.5%) growth increase,
Figure 4. CTAs and associated target genes are coordinately expressed in NSCLC. (A) Heat map of transcript expression as measured by
the Affymetrix Human Genome U133 Plus 2.0 mRNA expression platform. The data were first normalized by setting the mean and standard deviation
of each gene to 0 and 1 respectively across all 151 samples. The data were then clustered in the sample domain using hierarchical clustering with
average linkage and a Euclidean distance metric. (B) Pearson’s correlation coefficient p-value matrix for gene expression which tests for the
coexpression of each gene pair across all tumors. This comparison shows the expression correlation of each gene pair in 111 NSCLC. Values to the
upper right have been corrected with the Benjamin Hochberg multiple test correction to decrease the false discovery rate; uncorrected values are
displayed in the lower left. Shaded cells represent significant p-values.
doi:10.1371/journal.pone.0008189.g004
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respectively (Figure 5A). In H226 cells at 72 hours, NY-ESO-1 and
SBSN caused a 24% (612%) and 42% (64%) growth increase,
respectively (Figure S4A). In addition, both target genes were able
to induce increased AD growth in a normal lung fibroblast cell
line, MRC-5. At 72 hours post transfection, NY-ESO-1 induced a
63% (614.5%) increase in growth while SBSN induced a 56%
(65%) increase in growth (Figure 5C). Interestingly, neither gene
caused an increase in AD growth in lung adenocarcinoma cell line
A549 (Figure 5D).
In order to further evaluate the growth promoting potential of
these target genes, anchorage independent (AI) growth in soft agar
was measured following transient transfection with either SBSN or
NY-ESO-1 in NCI-H1703 and MRC-5 cell lines. Because the target
gene constructs used contained a G418 resistance cassette, all AI
growth assays were performed in the presence of G418. After 12
days in soft agar, H1703 cells transfected with NY-ESO-1 formed
significantly more colonies than their empty vector transfected
counterparts averaging 40 colonies versus 16 colonies, respectively
(p,0.03) (2 tailed Student’s t-test assuming unequal variance)
(Figure 5B). Although SBSN was able to cause a small increase in
colony formation, 19 versus 16, this data did not reach significance
(Figure S4B). Neither SBSN nor NY-ESO-1 were able to transform
the normal lung fibroblast cell line, MRC-5 (data not shown).
Discussion
The development of vaccines aimed at inducing an active
specific cytotoxic immune response in NSCLC has been met with
many challenges, including the lack of suitable target antigens
[16]. Although NY-ESO-1 and MAGEA3 are currently undergo-
ing clinical trials in various human malignancies, including
NSCLC, the use of single antigen vaccine formulations have
often been met with limited clinical outcomes [14,15,16,30]. The
identification of multiple, tumor specific antigens may facilitate the
use of more effective polyvalent cancer vaccines; however, this
requires the identification of multiple aberrantly expressed genes,
as well as an understanding of the patterns of expression that are
prevalent in the tumor of interest [15,16,31].
In this study, we used a novel, integrative epigenetic screening
approach to specifically look for coordinately expressed genes in
Figure 5. SBSN and NY-ESO-1 are growth promoting in normal and NSCLC cell lines. (A) Anchorage dependent growth following transient
transfection of NY-ESO-1 or SBSN construct into NCI-H1703 cells (at 72 hours, 23% (612%) and 47% (66.5%) growth increase, respectively). (B)
Anchorage independent growth was assayed in NCI-H1703 cells following transfection with empty vector (EV) or NY-ESO-1. NY-ESO-1 significantly
increased the number of colonies formed, 40 versus 16 (p,0.03) (2 tailed Student’s t-test assuming unequal variance). (C) Anchorage dependent
growth following transient transfection of NY-ESO-1 or SBSN construct into normal lung fibroblast cells,MRC-5, (at 72 hours, 63% (614.5%) and 56%
(65%) growth increase, respectively). (D) Anchorage dependent growth following transient transfection of NY-ESO-1 or SBSN construct into lung
adenocarinoma cells, A549, (neither gene caused a significant increase in growth at 72 hours).
doi:10.1371/journal.pone.0008189.g005
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human NSCLC whose transcription is driven by promoter
demethylation. From the over 47,000 transcripts incorporated in
the Affymetrix HumanGenomeU133 Plus 2.0 expression platform,
we were able to identify 10 genes that showed both differential
overexpression and promoter region hypomethylation in NSCLC.
Surprisingly, 6 of the 10 genes discovered via this approach were
known CT-X antigens,MAGEA3, MAGEA12, MAGEA4, MAGEA1,
MAGEA5 and NY-ESO-1. Four additional CTAs, MAGEA9,
MAGEA6, MAGEB2 and CT45-2, were within the top 20 on our
rank list; however, these genes did not meet our screening selection
criteria due to failure to show complete methylation of promoter
regions in our separate cohort of normal lung tissue by bisulfite
sequencing (Table S2). It is possible that, by using less stringent
selection criteria, we would identify these and other genes as
differentially expressed, albeit with incomplete promoter methyla-
tion patterns in normal lung tissue. In this study we selected only the
top 55 of the 290 possible targets identified after integrative analysis
in a single solid tumor type for further analysis. It is our expectation
that further investigation of the remaining genes, as well as the use of
normal cell lines and tumors derived from additional tissue types in
an integrative approach, will allow for discovery of additional,
novel, epigenetically-controlled genes that may also show coordi-
nated expression in tumors and serve as possible targets for
screening and immunogenic therapy.
Although some of the CTAs we identified using this technique
have previously been shown to be expressed to some degree in
NSCLC; the demonstration of a high degree of coordinated
expression in a large sample set related to epigenetic unmasking is
a novel finding [26,31,32,33,34,35,36]. In a previous study of 19
lung carcinoma cell lines expressing various MAGEA family
members, there was nearly complete concordance between the
RT-PCR and IHC results [34]. Thus the use of quantitative RT-
PCR is a valid method for detecting CT antigen expression,
especially when dealing with primary tissue where it is usually not
possible to isolate sufficient quantities of protein for analysis. In
addition, this same study showed that 44% of the 187 NSCLC
samples tested on tissue microarrays stained positive, to some
degree, for MAGEA family expression, supporting the fact that
CTAs are expressed at the protein level in NSCLC [34].
Four target genes showed a significant positive correlation
between mRNA expression and promoter hypomethylation,
MAGEA12, MAGEA4, SBSN and NY-ESO-1 (Figure S3A2D).
TKTL1, MAGEA5 and MAGEA3 also showed a positive correlation
between demethylation and expression, but missed significance
(Table S3). The lack of correlation between expression and
hypomethylation in some of our target genes is expected given the
fact that multiple other mechanisms such as point mutations,
insertions, deletions and loss of heterozygosity could be involved in
gene expression regulation in NSCLC. Alternatively, a larger
sample size may facilitate the ability to define a closer association
between promoter methylation status and expression in these genes.
In addition to the 6 mentioned CT-X antigens, our discovery
approach elucidated 4 additional target genes that we showed to
be coordinately expressed with the known CTAs and demethyl-
ated in tumors. Interestingly, three of these 4 genes are encoded by
the X chromosome, TKTL-1, ZNF-711 and G6PD. TKTL1 has
been correlated with worse outcomes in patients with invasive
colon and urothelial tumors, oxygen-independent glucose usage
and validated as a potential biomarker in breast cancer [37,38].
SBSN, ZNF-711 and G6PD have not previously been associated
with tumor specific expression or carcinogenesis.
We were also able to define a subset of NSCLC that
coordinately and aberrantly expressed these target genes. The
tight association of this subset with a squamous histology supports
the concept that tumors that express this gene cluster have a
distinct phenotype, and may preferentially express this cohort of
cancer testes antigens due to selection pressures.
CTAs are attractive targets for tumor immunotherapy because
of their restricted expression patterns in normal human tissue.
Currently, demethylating agents and HDAC inhibitors are being
studied as adjuvant treatment options for NSCLC and other
human malignancies, and combinations of these drugs continue to
undergo bench-top and clinical investigation [39,40,41]. These
epigenetic therapies are being utilized based on data that suggests
that methylation of tumor suppressor genes plays a fundamental
role in tumor formation, progression, and recurrence after
resection. Promoter region methylation of certain genes in resected
NSCLC specimens was recently shown to be associated with
recurrence of the tumor and poorer patient outcomes [42]. An
additional study has previously shown that NY-ESO-1 and
MAGEA3 are upregulated in a proportion of patients treated with
5-aza-29-deoxycytidine in cancers involving the lung, esophagus,
or pleura [41]. With our data suggesting that multiple CTAs are
coordinately expressed in NSCLC and demethylation coordinately
upregulates multiple known CTAs and associated genes from our
target list, it might be useful in the future to combine the use of
demethylating agents with immunotherapy targeted against these
genes that might be derepressed after treatment with 5-AZA and
other demethylating agents. Targeting multiple CTAs that are
coordinately expressed would help to improve the efficacy seen
with monovalent immunologic agents.
To date, the function of these genes expressed uniquely in
NSCLC has not been well explored. There are data that indicate
that MAGEA family members have growth promoting effects, and
CTA members have been associated with biologic pathways that
support a malignant phenotype. In this study, we showed that both
NY-ESO-1 and newly identified SBSN are growth promoting in
lung squamous cell carcinoma cell lines and normal lung
fibroblasts. Interestingly, neither gene product induced increased
cell growth in the lung adenocarcinoma cell line, supporting the
concept that these genes are tightly associated with the squamous
histologic subtype and their expression causes a selective growth
advantage in these cells. In addition we were able to show that NY-
ESO-1 was able to induce a significant increase in anchorage
independent cell growth, and, while, SBSN increased soft agar
growth, it was not significant (Figure 5 and Figure. S4). In the
future, we believe that additional analyses of other genes that are
aberrantly expressed via promoter demethylation in NSCLC
would be expected to demonstrate functional effects that
contribute to carcinogenesis, and may identify other potential
candidate proto-oncogenes that are activated via promoter
demethylation. Recent data in head and neck squamous cell
carcinoma indicates that similar strategies are effective in
identifying candidate proto-oncogenes [43].
Using an integrative analysis combining pharmacologic demeth-
ylation and previously published primary tissue array data, we have
defined a common epigenetic mechanism for the coordinated
expression of CTAs and defined additional targets that may serve as
targets for immunotherapy. In the future, the combined use of
coordinately expressed CTAs and related genes could aid in the
design of more effective, polyvalent immunotherapeutic protocols in
NSCLC and other tumor types, as well as identification of potential
therapeutic targets and candidate proto-oncogenes in NSCLC.
Supporting Information
Figure S1 Promoter demethylation causes transcriptional upre-
gulation. Relative fold upregulation after treatment with 5-aza/
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TSA is shown in NHBE and SAEC cell lines as measured by
quantitative RT-PCR. The ratio of 5-aza/TSA treated expression
to baseline with associated p values are shown for MAGEA3,
MAGEA4, MAGEA12, MAGEA1, SBSN, TKTL1, MAGEA5,
ZNF711, NY-ESO-1 and G6PD. Experiments were performed in
triplicate, the values are means 6 s.d. Each gene, with the
exception MAGEA12, demonstrated significant upregulation by
5-aza/TSA treatment in at least one cell line (2 tailed Student’s t-
test assuming unequal variance).
Found at: doi:10.1371/journal.pone.0008189.s001 (2.14 MB TIF)
Figure S2 Target gene expression is upregulated in NSCLC vs.
normal lung tissues. (A–J) Quantitative RT-PCR in a cohort of 28
NSCLC and 5 normal lung tissues. Significant increased
expression in tumors was seen for MAGEA12 (p,0.02), SBSN
(p,0.002), TKTL1 (p,0.02), ZNF711 (p,0.008), NY-ESO-1
(p,0.001), G6PD (p,0.006). Three genes slightly missed
significance at the a,0.05 level: MAGEA3 (p,0.09), MAGEA4
(p,0.06) and MAGEA1 (p,0.08) (2 tailed Student’s t-test
assuming unequal variance). Experiments were performed in
triplicate, values are mean 6 s.d.
Found at: doi:10.1371/journal.pone.0008189.s002 (2.26 MB PPT)
Figure S3 Gene transcript expression is correlated with
promoter demethylation. (a–d) Scatter plots showing Log2
QRT-PCR values plotted against Log2 QUMSP for 28 NSCLC
and 5 normal lung tissues. Significant positive correlation between
mRNA expression and promoter hypomethylation were seen for
MAGEA12 (p = 0.024), MAGEA4 (p,0.004), SBSN (p= 0.004)
and NY-ESO-1 (p,0.004) (Spearman’s correlation permutation
test).
Found at: doi:10.1371/journal.pone.0008189.s003 (1.72 MB TIF)
Figure S4 SBSN and NY-ESO-1 induce AD and AI growth in
lung SCC cell lines. (A) Anchorage dependent growth following
transient transfection of NY-ESO-1 or SBSN construct into NCI-
H226 cells (at 72 hours, 24% (612%) and 42% (64%) growth
increase, respectively). (B) Anchorage independent growth was
assayed in NCI-H1703 cells after transfection with empty vector
(EV), SBSN, or NY-ESO-1. Both SBSN and NY-ESO-1 induced
an increase in the number of colonies formed, but only NY-ESO-1
reached significance (p,0.03) (2 tailed Student’s t-test assuming
unequal variance).
Found at: doi:10.1371/journal.pone.0008189.s004 (0.34 MB TIF)
Table S1 Primer Sequences
Found at: doi:10.1371/journal.pone.0008189.s005 (0.02 MB
XLS)
Table S2 Supplementary Table 2. List of the 290 significant
genes found after combing the three rank ordered lists (- =Not
determined).
Found at: doi:10.1371/journal.pone.0008189.s006 (0.06 MB
PDF)
Table S3 Spearman’s correlation permutation test p value table
showing the strength of positive correlation between demethyla-
tion (QUMSP) and mRNA expression (RT-PCR).
Found at: doi:10.1371/journal.pone.0008189.s007 (0.34 MB TIF)
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